Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity

International Journal of Laboratory Hematology

Volumn 32, Issue 1 PART.1, 2010, Pages

  Jones, K ^a   Nourse, J ^a   Corbett, G ^b   Gandhi, M K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Waikato District Hospital   (New Zealand)

Author keywords

Epstein barr virus; Ganciclovir; Histone deacet ylase inhibitor; T Cell; Valproate

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BUTYRIC ACID; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GEMCITABINE; LATENT MEMBRANE PROTEIN 1; PENTOSTATIN; PREDNISOLONE; RITUXIMAB; VALPROIC ACID; VINCRISTINE; VIRUS DNA;

ADULT; ARTICLE; AXILLA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL FREE SYSTEM; CELLULAR IMMUNITY; CYTOLYSIS; EFFECTOR CELL; EPSTEIN BARR VIRUS; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LIVER; LYMPHOMA CELL; MALE; MEDIASTINUM; NONHUMAN; PRIORITY JOURNAL; REMISSION; SPLENECTOMY; VIRUS INFECTION;

ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; GANCICLOVIR; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; T-LYMPHOCYTES; VALPROIC ACID;

EID: 77249177223     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2008.01130.x     Document Type: Article

References (17)

1. Au W.Y., Pang A., Choy C., Chim C.S. & Kwong Y.L. (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood, 104, 243-249.
2. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P. & Gisselbrecht C. (2002) CHOP chemotherapy plus ritux- imab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
3. Detich N., Bovenzi V. & Szyf M. (2003) Valproate induces replication-independent active DNA demethylation. Journal of Biological Chemistry, 278, 27586-27592.
4. Dolcetti R., Guidoboni M., Gloghini A. & Carbone A. (2005) EBV-associated tumors: pathogenetic insights for improved disease monitoring and treatment. Current Cancer Therapy Reviews, 1, 27-44.
5. Feng W.H. & Kenney S.C. (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Research, 66, 8762-8769.
6. Feng W.H., Hong G., Delecluse H.J. & Kenney S.C. (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Journal of Virology, 78, 1893-1902.
7. Gandhi M.K. (2006a) Epstein-Barr virus- associated lymphomas. Expert Review of Anti-Infective Therapy, 4, 77-89.
8. Gandhi M.K., Lambley E., Burrows J., Dua U., Elliott S., Shaw P.J., Prince H.M., Wolf M., Clarke K., Underhill C., Mills T., Mollee P., Gill D., Marlton P., Seymour J.F. & Khanna R. (2006a) Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12, 460-464.
9. Gandhi M.K., Lambley E., Duraiswamy J., Dua U., Smith C., Elliott S., Gill D., Marlton P., Seymour J. & Khanna R. (2006b) Expression of LAG-3 by tumor- infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood, 108, 2280-2289.
10. Gandhi M.K., Moll G., Smith C., Dua U., Lambley E., Ramuz O., Gill D., Marlton P., Seymour J.F. & Khanna R. (2007) Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood, 110, 1326-1329.
11. Khanna R., Moss D. & Gandhi M.K. (2005) Technology insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nature Clinical Practice. Oncology, 2, 138-149.
12. Lechowicz M.J., Lin L. & Ambinder R.F. (2002) Epstein-Barr virus DNA in body fluids. Current Opinion in Oncology, 14, 533-537.
13. Lechowicz M.J., Lee J., Dittmer D., Krown S., Said J. & Ambinder R.F. (2007) A pilot trial of valproic acid in patients with Kaposi's sarcoma: a multi- center trial of the AIDS malignancy consortium. Blood, 110, a2279.
14. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S. & Jiang R.S. (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. New England Journal of Medicine, 350, 2461-2470.
15. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., Lee J.C., Hjelm N.M., Johnson P.J. & Huang D.P. (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Research, 59, 1188-1191.
16. Perrine S.P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., Fingeroth J., Askin M., Levy A., Mentzer S.J., Di Nicola M., Gianni A.M., Klein C., Horwitz S. & Faller D.V. (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood, 109, 2571-2578.
17. Young L.S. & Rickinson A.B. (2004) Epstein-Barr virus: 40 years on. Nature Reviews. Cancer, 4, 757-768.